Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Sarcoidosis natural history, complications and prognosis
Introduction
Overview
Overview
The overall mortality in sarcoidosis is low (about 5%), and many patients with spontaneous regression will never require treatment. Complications include pulmonary hypertension, fatigue, osteoporosis, aspergilloma, arrhythmias, and renal failure.
Natural History
Natural History
The overall mortality in sarcoidosis is low (about 5%), and many patients with spontaneous regression will never require treatment[1]. In people who need treatment, important differences exist between African-American and white patients. African-American patients with sarcoidosis experience a more severe and systemic disease and 12 times higher mortality [2]
Complications
Complications
- SAPH: sarcoidosis-associated pulmonary hypertension[3][4]
- Fatigue[5]
- Osteoporosis[6][7]
- Aspergilloma[8][9][10]
- Ventricular arrhythmias[11]
- Saddle nose defirmity
- Renal failure due to hypercalcemia and/or intersitial nephritis[12]
- Lung fibrosis
Prognosis
Prognosis
- African-American patients with sarcoidosis experience a more severe and systemic disease and 12 times higher mortality [2]
References
References
- ↑ Gerke AK: Morbidity and mortality in sarcoidosis. Curr Opin Pulm Med 20:472–478, 2014.
- ↑ 2.0 2.1 Mirsaeidi M, et al: Racial difference in sarcoidosis mortality in the United States. Chest 147:438–449, 2015.
- ↑ Fisher KA, Serlin DM, Wilson KC, et al: Sarcoidosis-associated pulmonary hypertension: outcome with long term epoprostenol treatment. Chest 130(5):1481–1488, 2006.
- ↑ Preston IR, Klinger JR, Landzberg MJ, et al: Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 120(3):866–872, 2001.
- ↑ de Kleijn WP, de Vries J, Lower EE, et al: Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 15(5):499–506, 2009.
- ↑ Kavathia D, Buckley JD, Rao D, et al: Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med 104(4):564–570, 2010.
- ↑ Gonnelli S, Rottoli P, Cepollaro C, et al: Prevention of corticosteroidinduced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 61(5):382–385, 1997.
- ↑ Denning DW, Pleuvry A, Cole DC: Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 41(3):621–626, 2013.
- ↑ Pena TA, Soubani AO, Samavati L: Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 189(2):167–172, 2011.
- ↑ Baughman RP, Lower EE: Fungal infections as a complication of therapy for sarcoidosis. QJM 98:451–456, 2005.
- ↑ Birnie DH, Sauer WH, Bogun F, et al: HRS expert concensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11(7):1305–1323, 2014.
- ↑ Mahevas M, Lescure FX, Boffa JJ, et al: Renal sarcoidosis: clinical, laboratory, and histologic presentation and outcome in 47 patients. Medicine (Baltimore) 88(2):98–106, 2009.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roshan Dinparasti Saleh M.D.